title: Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
abstract: OBJECTIVE
  To analyse changes in lipid profiles observed in patients receiving androgen deprivation therapy (ADT) and to evaluate differences between medical castration and maximal androgen blockade (MAB).
  
  
  METHODS
  Serum levels of total cholesterol (TC), high-density lipoproteins (HDL), low-density lipoproteins (LDL) and triglycerides (TG) were prospectively evaluated in 33 patients with locally advanced or metastatic prostate cancer treated with ADT. The median age was 73.4 years. Serum lipids were measured at baseline and thereafter at 6 and 12 months. The modality of ADT was medical, with 3 months depot LHRH agonist, in 11 patients and MAB, by addition of 50 mg/day of bicalutamide, in 22 patients.
  
  
  RESULTS
  TC increased from 210 to 227 mg/dl (p < 0.05), while LDL increased from 132 to 148 mg/dl (p < 0.05) at 6 months. There were no significant changes in HDL or TG levels. There were no significant differences in any of the analysed parameters after 12 months of ADT. The comparison between the group of patients treated with LHRH agonists alone and the group treated with MAB demonstrated no significant differences in any of the analysed parameters at 6 and 12 months (p > 0.05).
  
  
  CONCLUSIONS
  Changes observed in TC and LDL after 6 months of ADT were transitory. No significant differences were observed according to the modality of ADT.
authors.affiliation: Department of Urology, Hospital Vall d'Hebron, Barcelona, Spain. casalvad @ vhebron.net
authors.forename: C
authors.initials: C
authors.lastname: Salvador
authors.forename: J
authors.initials: J
authors.lastname: Planas
authors.forename: F
authors.initials: F
authors.lastname: Agreda
authors.forename: J
authors.initials: J
authors.lastname: Placer
authors.forename: E
authors.initials: E
authors.lastname: Trilla
authors.forename: M A
authors.initials: MA
authors.lastname: Lopez
authors.forename: J
authors.initials: J
authors.lastname: Morote
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology*; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D009361:Neoplasm Invasiveness; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009570:Nitriles / Q000627:therapeutic use; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D012307:Risk Factors; D013997:Time Factors; D014105:Tosyl Compounds / Q000627:therapeutic use; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D009570:Nitriles; D014105:Tosyl Compounds; D014280:Triglycerides; D007987:Gonadotropin-Releasing Hormone; D002784:Cholesterol; C053541:bicalutamide